Treatment options for patients with severe COVID-19

The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patien...

Full description

Saved in:
Bibliographic Details
Published inGlobal Health & Medicine Vol. 5; no. 2; pp. 99 - 105
Main Authors Morishita, Momoko, Hojo, Masayuki
Format Journal Article
LanguageEnglish
Published Japan National Center for Global Health and Medicine 30.04.2023
Subjects
anticoagulation therapy
high-flow nasal cannula therapy
immune-based agents
remdesivir
Review
high-flow nasal cannula therapy
anticoagulation therapy
remdesivir
immune-based agents
Online AccessGet full text

Cover

Abstract The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.
AbstractList The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.
The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period, including antiviral drugs, antibody drugs, immune-based agents, and vaccination. While these improvements have reduced mortality rates in patients with COVID-19, some patients still develop severe illness. In this review, we aimed to provide an overview of treatments for patients with severe COVID-19 from study reports and clinical experience. We discussed the treatments from two perspectives: respiratory care and drug treatments. In the respiratory care section, we discussed the usefulness of high-flow nasal cannula therapy and non-invasive ventilation as an alternative to invasive ventilation. In the drug treatments section, we focused on three classes for severe COVID-19 treatment: antiviral drugs, immune-based agents, and anticoagulation therapy. We did not discuss antibody drugs and vaccination, as they are not used for severe COVID-19 treatment.
ArticleNumber 2023.01024
Author Hojo, Masayuki
Morishita, Momoko
Author_xml – sequence: 1
  fullname: Morishita, Momoko
  organization: Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
– sequence: 2
  fullname: Hojo, Masayuki
  organization: Department of Respiratory Medicine, National Center for Global Health and Medicine, Tokyo, Japan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37128231$$D View this record in MEDLINE/PubMed
BookMark eNp9kctP3DAQxq2KqjzKuTeUYy9Z_CTOCdHlKSFxAa7WxJnsukrixfZS9b_HuwtR20MPli3P7_tmNN8h2Rv9iIR8Y3QmVFXx08VymHHKxYwyyuUncsClkGXNark3vfXZPjmO0TVUcslErekXsi8qxjUX7ICIx4CQBhxT4VfJ-TEWnQ_FCpLLf7H45dKyiPiKAYv5w_PdZcnqr-RzB33E4_f7iDxdXz3Ob8v7h5u7-cV9aWUlUslo2yDtQMtOys4iKg6ipqJSGiTUoBsQmnLangloVQ2yAlU1QtmWZZpxcUTOd76rdTNga_NAAXqzCm6A8Nt4cObvyuiWZuFfDaNMUCV1dvj-7hD8yxpjMoOLFvseRvTraLimWulKMpbRkz-bTV0-VpWB0x1gg48xYDchjJptHibnYTZ5mG0eWaH-UViXYLPkPK3r_6P7sdP9jAkWOPWBkJztcYsrwzdnEk1Fu4RgcBRvQJil5g
CitedBy_id crossref_primary_10_15789_2220_7619_AUR_15080
Cites_doi 10.1001/jama.2020.16349
10.1177/00368504211030372
10.1186/s13613-020-00653-z
10.1097/CCM.0000000000004558
10.1001/jamainternmed.2020.6615
10.1056/NEJMoa2030340
10.1001/jama.2021.4152
10.1056/NEJMoa2021436
10.1183/13993003.00892-2020
10.15252/emmm.202012697
10.1016/j.chest.2020.03.043
10.1016/S2665-9913(20)30173-9
10.1056/NEJMoa2028836
10.1136/bmj.n2400
10.1016/j.medmal.2020.05.001
10.1183/13993003.02339-2018
10.1016/S0140-6736(20)30361-5
10.1016/j.cytogfr.2020.05.003
10.1016/j.jacc.2020.04.031
10.1164/rccm.200503-353OC
10.1136/bmj-2021-069317
10.1001/jama.2016.0291
10.1001/jama.2020.5394
10.1007/s11684-020-0824-3
10.1016/S0140-6736(20)31189-2
10.1016/j.jacc.2020.05.001
10.1056/NEJMoa2103417
10.1183/13993003.00025-2022
10.1136/bmj.n311
10.1111/resp.14106
10.1136/bmj.n84
10.1503/cmaj.201240
10.1182/blood.2020006000
10.1513/AnnalsATS.202005-427RL
10.1007/s00134-020-06251-8
10.1002/jmv.25801
10.1016/S0140-6736(21)01203-4
10.1164/rccm.201803-0589OC
10.1097/CCM.0000000000004457
10.1007/s12630-020-01740-2
10.1038/s41467-020-20542-0
10.1016/j.resinv.2021.02.011
10.1183/13993003.02524-2020
10.3390/jcm9082489
10.1080/13543784.2020.1840549
10.1183/13993003.01692-2020
10.1186/s13054-021-03540-6
10.1016/j.tips.2020.06.007
10.1016/S0140-6736(20)31022-9
10.1097/CCM.0000000000004600
10.1016/S2213-2600(21)00331-3
10.1186/s40001-022-00953-z
10.1164/rccm.202005-2007LE
10.1016/S1473-3099(21)00485-0
10.1001/jamainternmed.2021.2209
10.1016/j.jacc.2021.12.023
10.1097/CCE.0000000000000254
10.1016/S2213-2600(16)30093-5
10.1021/acscentsci.0c00489
10.1183/13993003.01426-2022
10.1016/S0140-6736(21)00676-0
10.1056/NEJMoa2031994
10.1007/s00134-019-05590-5
10.1016/S2213-2600(21)00081-3
10.1007/s40265-018-0908-4
10.1016/j.jacc.2020.08.041
10.1371/journal.pone.0252760
10.1016/S0140-6736(22)01109-6
10.1056/NEJMc2022236
10.1016/j.eclinm.2020.100419
10.1056/NEJMoa2002032
10.1056/NEJMoa2100433
10.1016/j.eclinm.2020.100639
10.1097/CCM.0000000000002361
10.1016/S0140-6736(20)30317-2
10.1038/s41598-020-78054-2
10.1007/s00134-015-3693-5
10.1183/13993003.01935-2020
10.1001/jama.2020.6775
10.1016/j.eclinm.2020.100570
10.1001/jama.2020.17023
10.1016/j.jiac.2022.02.006
10.1007/s00134-013-3194-3
10.1002/14651858.CD004104.pub4
10.1016/S0140-6736(20)30304-4
10.1056/NEJMoa2028700
10.1001/jamainternmed.2021.6203
10.1056/NEJMoa2023184
10.1183/13993003.02426-2016
ContentType Journal Article
Copyright 2023 National Center for Global Health and Medicine
2023, National Center for Global Health and Medicine.
2023, National Center for Global Health and Medicine 2023
Copyright_xml – notice: 2023 National Center for Global Health and Medicine
– notice: 2023, National Center for Global Health and Medicine.
– notice: 2023, National Center for Global Health and Medicine 2023
DBID AAYXX
CITATION
NPM
7X8
5PM
DOI 10.35772/ghm.2023.01024
DatabaseName CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList

MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Public Health
EISSN 2434-9194
EndPage 105
ExternalDocumentID PMC10130548
37128231
10_35772_ghm_2023_01024
article_ghm_5_2_5_2023_01024_article_char_en
Genre Journal Article
Review
GroupedDBID ALMA_UNASSIGNED_HOLDINGS
JSF
JSH
RJT
RPM
RZJ
AAYXX
CITATION
NPM
7X8
5PM
ID FETCH-LOGICAL-c473t-10dbe0fa84f44fcee52a3903758a4a9a8ba38020d63ad59a47a57b35cd1fce123
ISSN 2434-9186
2434-9194
IngestDate Thu Aug 21 18:37:51 EDT 2025
Fri Jul 11 07:45:07 EDT 2025
Thu Jan 02 22:52:33 EST 2025
Thu Apr 24 23:13:12 EDT 2025
Tue Jul 01 03:36:53 EDT 2025
Sun Jul 28 05:37:19 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords high-flow nasal cannula therapy
anticoagulation therapy
remdesivir
immune-based agents
Language English
License 2023, National Center for Global Health and Medicine.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c473t-10dbe0fa84f44fcee52a3903758a4a9a8ba38020d63ad59a47a57b35cd1fce123
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
OpenAccessLink https://www.jstage.jst.go.jp/article/ghm/5/2/5_2023.01024/_article/-char/en
PMID 37128231
PQID 2808587411
PQPubID 23479
PageCount 7
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_10130548
proquest_miscellaneous_2808587411
pubmed_primary_37128231
crossref_primary_10_35772_ghm_2023_01024
crossref_citationtrail_10_35772_ghm_2023_01024
jstage_primary_article_ghm_5_2_5_2023_01024_article_char_en
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 20230430
PublicationDateYYYYMMDD 2023-04-30
PublicationDate_xml – month: 4
  year: 2023
  text: 20230430
  day: 30
PublicationDecade 2020
PublicationPlace Japan
PublicationPlace_xml – name: Japan
PublicationTitle Global Health & Medicine
PublicationTitleAlternate GHM
PublicationYear 2023
Publisher National Center for Global Health and Medicine
Publisher_xml – name: National Center for Global Health and Medicine
References 22. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017; 50:1602426.
69. Shang L, Lye DC, Cao B. Contemporary narrative review of treatment options for COVID-19. Respirology. 2021; 26:745-767.
33. Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, Jabaley CS, Carpenter D, Kaplow R, Hernandez-Romieu AC, Adelman MW, Martin GS, Coopersmith CM, Murphy DJ. ICU and ventilator mortality among critically Ill adults with coronavirus disease 2019. Crit Care Med. 2020; 48:e799-e804.
55. Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs. 2020; 29:1407-1412.
54. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25-32.
6. Demoule A, Vieillard Baron A, Darmon M, Beurton A, Géri G, Voiriot G, Dupont T, Zafrani L, Girodias L, Labbé V, Dres M, Fartoukh M, Azoulay E. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020; 202:1039-1042.
8. Xia J, Zhang Y, Ni L, Chen L, Zhou C, Gao C, Wu X, Duan J, Xie J, Guo Q, Zhao J, Hu Y, Cheng Z, Zhan Q. High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure: A multicenter, retrospective cohort study. Crit Care Med. 2020; 48:e1079-e1086.
57. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020; 50:397-400.
81. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135:2033-2040.
92. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021; 385:777-789.
61. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020; 383:2333-2344.
41. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395:1569- 1578.
34. Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY, Moharram AA. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis. PLoS One. 2021; 16:e0252760.
7. Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020; 28:100570.
19. Xu XP, Zhang XC, Hu SL, Xu JY, Xie JF, Liu SQ, Liu L, Huang YZ, Guo FM, Yang Y, Qiu HB. Noninvasive ventilation in acute hypoxemic nonhypercapnic respiratory failure: A systematic review and meta-analysis. Crit Care Med. 2017; 45:e727-e733.
47. Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, Tateda K, Hiramatsu K, Kadota JI. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci Rep. 2020; 10:20935.
15. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, Gin T, Chan MTV. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019; 53:1802339.
1. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int (accessed March 15, 2023).
78. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9:1407-1418.
10. Lee HJ, Kim J, Choi M, Choi WI, Joh J, Park J, Kim J. Efficacy and safety of prone position in COVID-19 patients with respiratory failure: A systematic review and meta-analysis. Eur J Med Res. 2022; 27:310.
24. Aliberti S, Radovanovic D, Billi F, Sotgiu G, Costanzo M, Pilocane T, Saderi L, Gramegna A, Rovellini A, Perotto L, Monzani V, Santus P, Blasi F. Helmet CPAP treatment in patients with COVID-19 pneumonia: A multicentre cohort study. Eur Respir J. 2020; 56:2001935.
28. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323:2052-2059.
53. Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: A double-blind, randomised, placebo-controlled trial. Eur Respir J. 2022; 60:2200025.
77. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384:795-807.
67. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021; 9:511-521.
75. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395:e30-e31.
90. INSPIRATION Investigators; Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA. 2021; 325:1620-1630.
80. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020; 76:122-124.
89. Farkouh ME, Stone GW, Lala A, et al. Anticoagulation in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2022; 79:917-28.
44. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med. 2020; 383:1813-1826.
25. Brusasco C, Corradi F, Di Domenico A, Raggi F, Timossi G, Santori G, Brusasco V; Galliera CPAP-Covid-19 study group; collaborators of the Galliera CPAP-COVID-19 study group care. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure. Eur Respir J. 2021; 57:2002524.
20. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 7:CD004104.
37. Papoutsi E, Giannakoulis VG, Xourgia E, Routsi C, Kotanidou A, Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: A systematic review and meta-analysis of non-randomized cohort studies. Crit Care. 2021; 25:121.
26. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, Llontop C, Guerder A, Trosini-Desert V, Faure M, Raux M, Decavele M, Demoule A, Morélot-Panzini C, Similowski T. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: A two-period retrospective case-control study. Eur Respir J. 2020; 56:2001692.
94. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. Lancet. 2021; 397:2253-2263.
84. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100639.
42. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022; 22:209-221.
68. Wang D, Fu B, Peng Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021; 15:486-494.
71. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA. 2021; 326:499-518.
29. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323:1574-1581.
17. Leonard S, Atwood CW, Walsh BK, DeBellis RJ, Dungan GC, Strasser W, Whittle JS. Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: Implications for the high-flow nasal cannula. Chest. 2020; 158:1046-1049.
21. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315:788-800.
56. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020; 2:e474-e484.
14. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019; 199:1368-1376.
59. Hermine O, Mariette X, Tharaux
44
88
45
89
46
47
48
49
90
91
92
93
50
94
51
52
53
10
54
11
55
12
56
13
57
14
58
15
59
16
17
18
19
1
2
3
4
5
6
7
8
9
60
61
62
63
20
64
21
65
22
66
23
67
24
68
25
69
26
27
28
29
70
71
72
73
30
74
31
75
32
76
33
77
34
78
35
79
36
37
38
39
80
81
82
83
40
84
41
85
42
86
43
87
References_xml – reference: 45. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: A randomized clinical trial. JAMA. 2020; 324:1048-1057.
– reference: 84. Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020; 29:100639.
– reference: 40. Kokic G, Hillen HS, Tegunov D, Dienemann C, Seitz F, Schmitzova J, Farnung L, Siewert A, Höbartner C, Cramer P. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir. Nat Commun. 2021; 12:279.
– reference: 16. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion. Eur Respir J. 2020; 55:2000892.
– reference: 31. Schenck EJ, Hoffman K, Goyal P, Choi J, Torres L, Rajwani K, Tam CW, Ivascu N, Martinez FJ, Berlin DA. Respiratory mechanics and gas exchange in COVID-19-associated respiratory failure. Ann Am Thorac Soc. 2020; 17:1158-1161.
– reference: 86. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382:1708-1720.
– reference: 90. INSPIRATION Investigators; Sadeghipour P, Talasaz AH, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: The INSPIRATION randomized clinical trial. JAMA. 2021; 325:1620-1630.
– reference: 61. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020; 383:2333-2344.
– reference: 93. Spyropoulos AC, Goldin M, Giannis D, et al. Efficacy and safety of therapeutic-dose heparin vs standard prophylactic or intermediate-dose heparins for thromboprophylaxis in high-risk hospitalized patients with COVID-19: The HEP-COVID randomized clinical trial. JAMA Intern Med. 2021; 181:1612-1620.
– reference: 26. Oranger M, Gonzalez-Bermejo J, Dacosta-Noble P, Llontop C, Guerder A, Trosini-Desert V, Faure M, Raux M, Decavele M, Demoule A, Morélot-Panzini C, Similowski T. Continuous positive airway pressure to avoid intubation in SARS-CoV-2 pneumonia: A two-period retrospective case-control study. Eur Respir J. 2020; 56:2001692.
– reference: 30. Ferrando C, Suarez-Sipmann F, Mellado-Artigas R, et al. Clinical features, ventilatory management, and outcome of ARDS caused by COVID-19 are similar to other causes of ARDS. Intensive Care Med. 2020; 46:2200-2211.
– reference: 50. RECOVERY Collaborative Group; Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384:693-704.
– reference: 33. Auld SC, Caridi-Scheible M, Blum JM, Robichaux C, Kraft C, Jacob JT, Jabaley CS, Carpenter D, Kaplow R, Hernandez-Romieu AC, Adelman MW, Martin GS, Coopersmith CM, Murphy DJ. ICU and ventilator mortality among critically Ill adults with coronavirus disease 2019. Crit Care Med. 2020; 48:e799-e804.
– reference: 75. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, Rawling M, Savory E, Stebbing J. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020; 395:e30-e31.
– reference: 81. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020; 135:2033-2040.
– reference: 44. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - Final report. N Engl J Med. 2020; 383:1813-1826.
– reference: 82. Bikdeli B, Madhavan MV, Jimenez D, et al. COVID-19 and thrombotic or thromboembolic disease: Implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am Coll Cardiol. 2020; 75:2950-2973.
– reference: 83. Godoy LC, Goligher EC, Lawler PR, Slutsky AS, Zarychanski R. Anticipating and managing coagulopathy and thrombotic manifestations of severe COVID-19. CMAJ. 2020; 192:E1156-E1161.
– reference: 47. Shuto H, Komiya K, Yamasue M, Uchida S, Ogura T, Mukae H, Tateda K, Hiramatsu K, Kadota JI. A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19. Sci Rep. 2020; 10:20935.
– reference: 24. Aliberti S, Radovanovic D, Billi F, Sotgiu G, Costanzo M, Pilocane T, Saderi L, Gramegna A, Rovellini A, Perotto L, Monzani V, Santus P, Blasi F. Helmet CPAP treatment in patients with COVID-19 pneumonia: A multicentre cohort study. Eur Respir J. 2020; 56:2001935.
– reference: 58. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020; 92:814-818.
– reference: 7. Calligaro GL, Lalla U, Audley G, et al. The utility of high-flow nasal oxygen for severe COVID-19 pneumonia in a resource-constrained setting: A multi-centre prospective observational study. EClinicalMedicine. 2020; 28:100570.
– reference: 32. Cummings MJ, Baldwin MR, Abrams D, Jacobson SD, Meyer BJ, Balough EM, Aaron JG, Claassen J, Rabbani LE, Hastie J, Hochman BR, Salazar-Schicchi J, Yip NH, Brodie D, O'Donnell MR. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: A prospective cohort study. Lancet. 2020; 395:1763-1770.
– reference: 57. Klopfenstein T, Zayet S, Lohse A, et al. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients. Med Mal Infect. 2020; 50:397-400.
– reference: 92. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators; et al. Therapeutic anticoagulation with heparin in critically Ill patients with Covid-19. N Engl J Med. 2021; 385:777-789.
– reference: 35. Riera J, Barbeta E, Tormos A, et al. Effects of intubation timing in patients with COVID-19 throughout the four waves of the pandemic: A matched analysis. Eur Respir J. 2023; 61:2201426.
– reference: 22. Rochwerg B, Brochard L, Elliott MW, et al. Official ERS/ATS clinical practice guidelines: noninvasive ventilation for acute respiratory failure. Eur Respir J. 2017; 50:1602426.
– reference: 49. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020; 395:683-684.
– reference: 29. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323:1574-1581.
– reference: 79. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022; 400:359-368.
– reference: 91. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ. 2021; 375:n2400.
– reference: 9. Wang K, Zhao W, Li J, Shu W, Duan J. The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China. Ann Intensive Care. 2020; 10:37.
– reference: 12. Beitler JR, Shaefi S, Montesi SB, Devlin A, Loring SH, Talmor D, Malhotra A. Prone positioning reduces mortality from acute respiratory distress syndrome in the low tidal volume era: A meta-analysis. Intensive Care Med. 2014; 40:332-341.
– reference: 34. Elsayed HH, Hassaballa AS, Ahmed TA, Gumaa M, Sharkawy HY, Moharram AA. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis. PLoS One. 2021; 16:e0252760.
– reference: 42. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): A phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2022; 22:209-221.
– reference: 43. WHO Solidarity Trial Consortium; Pan H, Peto R, et al. Repurposed antiviral drugs for Covid-19 - Interim WHO solidarity trial results. N Engl J Med. 2021; 384:497-511.
– reference: 37. Papoutsi E, Giannakoulis VG, Xourgia E, Routsi C, Kotanidou A, Siempos II. Effect of timing of intubation on clinical outcomes of critically ill patients with COVID-19: A systematic review and meta-analysis of non-randomized cohort studies. Crit Care. 2021; 25:121.
– reference: 87. Nadkarni GN, Lala A, Bagiella E, et al. Anticoagulation, bleeding, mortality, and pathology in hospitalized patients with COVID-19. J Am Coll Cardiol. 2020; 76:1815-1826.
– reference: 19. Xu XP, Zhang XC, Hu SL, Xu JY, Xie JF, Liu SQ, Liu L, Huang YZ, Guo FM, Yang Y, Qiu HB. Noninvasive ventilation in acute hypoxemic nonhypercapnic respiratory failure: A systematic review and meta-analysis. Crit Care Med. 2017; 45:e727-e733.
– reference: 76. Stebbing J, Krishnan V, de Bono S, et al. Mechanism of baricitinib supports artificial intelligence-predicted testing in COVID-19 patients. EMBO Mol Med. 2020; 12:e12697.
– reference: 85. Chi G, Lee JJ, Jamil A, Gunnam V, Najafi H, Memar Montazerin S, Shojaei F, Marszalek J. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: A systematic review and meta-analysis. J Clin Med. 2020; 9:2489.
– reference: 25. Brusasco C, Corradi F, Di Domenico A, Raggi F, Timossi G, Santori G, Brusasco V; Galliera CPAP-Covid-19 study group; collaborators of the Galliera CPAP-COVID-19 study group care. Continuous positive airway pressure in COVID-19 patients with moderate-to-severe respiratory failure. Eur Respir J. 2021; 57:2002524.
– reference: 5. Agarwal A, Basmaji J, Muttalib F, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: Systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Can J Anaesth. 2020; 67:1217-1248.
– reference: 88. Rentsch CT, Beckman JA, Tomlinson L, et al. Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study. BMJ. 2021; 372:n311.
– reference: 55. Zhou Z, Price CC. Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs. 2020; 29:1407-1412.
– reference: 78. Marconi VC, Ramanan AV, de Bono S, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021; 9:1407-1418.
– reference: 80. Paranjpe I, Fuster V, Lala A, Russak AJ, Glicksberg BS, Levin MA, Charney AW, Narula J, Fayad ZA, Bagiella E, Zhao S, Nadkarni GN. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J Am Coll Cardiol. 2020; 76:122-124.
– reference: 8. Xia J, Zhang Y, Ni L, Chen L, Zhou C, Gao C, Wu X, Duan J, Xie J, Guo Q, Zhao J, Hu Y, Cheng Z, Zhan Q. High-flow nasal oxygen in coronavirus disease 2019 patients with acute hypoxemic respiratory failure: A multicenter, retrospective cohort study. Crit Care Med. 2020; 48:e1079-e1086.
– reference: 89. Farkouh ME, Stone GW, Lala A, et al. Anticoagulation in patients with COVID-19: JACC review topic of the week. J Am Coll Cardiol. 2022; 79:917-28.
– reference: 10. Lee HJ, Kim J, Choi M, Choi WI, Joh J, Park J, Kim J. Efficacy and safety of prone position in COVID-19 patients with respiratory failure: A systematic review and meta-analysis. Eur J Med Res. 2022; 27:310.
– reference: 39. Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD. Remdesivir: A review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci. 2020; 6:672-683.
– reference: 48. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020; 395:473-475.
– reference: 77. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med. 2021; 384:795-807.
– reference: 68. Wang D, Fu B, Peng Z, et al. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial. Front Med. 2021; 15:486-494.
– reference: 2. Suthar AB, Wang J, Seffren V, Wiegand RE, Griffing S, Zell E. Public health impact of covid-19 vaccines in the US: Observational study. BMJ. 2022; 377:e069317.
– reference: 27. Frat JP, Ragot S, Girault C, Perbet S, Prat G, Boulain T, Demoule A, Ricard JD, Coudroy R, Robert R, Mercat A, Brochard L, Thille AW; REVA network. Effect of non-invasive oxygenation strategies in immunocompromised patients with severe acute respiratory failure: A post-hoc analysis of a randomised trial. Lancet Respir Med. 2016; 4:646-652.
– reference: 13. Kang BJ, Koh Y, Lim CM, Huh JW, Baek S, Han M, Seo HS, Suh HJ, Seo GJ, Kim EY, Hong SB. Failure of high-flow nasal cannula therapy may delay intubation and increase mortality. Intensive Care Med. 2015; 41:623-632.
– reference: 14. Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An index combining respiratory rate and oxygenation to predict outcome of nasal high-flow therapy. Am J Respir Crit Care Med. 2019; 199:1368-1376.
– reference: 3. Infectious Diseases Society of America. IDSA guidelines on the treatment and management of patients with COVID-19. https://www.idsociety.org/practice-guideline/covid-19-guideline-treatment-and-management (accessed March 15, 2023).
– reference: 63. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: Randomised controlled trial. BMJ. 2021; 372:n84.
– reference: 56. Guaraldi G, Meschiari M, Cozzi-Lepri A, et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol. 2020; 2:e474-e484.
– reference: 66. RECOVERY Collaborative Group.Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial. Lancet. 2021; 397:1637-1645.
– reference: 65. REMAP-CAP Investigators; Gordon AC, Mouncey PR, et al. Interleukin-6 receptor antagonists in critically Ill patients with Covid-19. N Engl J Med. 2021; 384:1491-1502.
– reference: 15. Hui DS, Chow BK, Lo T, Tsang OTY, Ko FW, Ng SS, Gin T, Chan MTV. Exhaled air dispersion during high-flow nasal cannula therapy versus CPAP via different masks. Eur Respir J. 2019; 53:1802339.
– reference: 64. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021; 384:1503-1516.
– reference: 11. Mancebo J, Fernández R, Blanch L, et al. A multicenter trial of prolonged prone ventilation in severe acute respiratory distress syndrome. Am J Respir Crit Care Med. 2006; 173:1233-1239.
– reference: 59. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P; CORIMUNO-19 Collaborative Group. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: A randomized clinical trial. JAMA Intern Med. 2021; 181:32-40.
– reference: 38. Hernandez-Romieu AC, Adelman MW, Hockstein MA, Robichaux CJ, Edwards JA, Fazio JC, Blum JM, Jabaley CS, Caridi-Scheible M, Martin GS, Murphy DJ, Auld SC. Timing of intubation and mortality among critically Ill coronavirus disease 2019 patients: A single-center cohort study. Crit Care Med. 2020; 48:e1045-e1053.
– reference: 6. Demoule A, Vieillard Baron A, Darmon M, Beurton A, Géri G, Voiriot G, Dupont T, Zafrani L, Girodias L, Labbé V, Dres M, Fartoukh M, Azoulay E. High-flow nasal cannula in critically III patients with severe COVID-19. Am J Respir Crit Care Med. 2020; 202:1039-1042.
– reference: 62. Salama C, Han J, Yau L, et al. Tocilizumab in patients Hospitalized with Covid-19 Pneumonia. N Engl J Med. 2021; 384:20-30.
– reference: 67. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): An open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021; 9:511-521.
– reference: 36. Hyman JB, Leibner ES, Tandon P, Egorova NN, Bassily-Marcus A, Kohli-Seth R, Arvind V, Chang HL, Lin HM, Levin MA. Timing of intubation and in-hospital mortality in patients with coronavirus disease 2019. Crit Care Explor. 2020; 2:e0254.
– reference: 46. National Institutes of Health. Therapeutic management of hospitalized adults with COVID-19. https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/hospitalized-adults--therapeutic-management (accessed March 15, 2023).
– reference: 72. World Health Organization. Therapeutics and COVID-19: Living guideline, 13 January 2023. https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2023.1 (accessed March 15, 2023).
– reference: 60. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern Med. 2021; 181:24-31.
– reference: 74. Luo W, Li YX, Jiang LJ, Chen Q, Wang T, Ye DW. Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19. Trends Pharmacol Sci. 2020; 41:531-543.
– reference: 52. Morishita M, Suzuki M, Matsunaga A, et al. Prolonged SARS-CoV-2 infection associated with long-term corticosteroid use in a patient with impaired B-cell immunity. J Infect Chemother. 2022; 28:971-974.
– reference: 69. Shang L, Lye DC, Cao B. Contemporary narrative review of treatment options for COVID-19. Respirology. 2021; 26:745-767.
– reference: 94. Lopes RD, de Barros E Silva PGM, Furtado RHM, et al. Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): An open-label, multicentre, randomised, controlled trial. Lancet. 2021; 397:2253-2263.
– reference: 21. Bellani G, Laffey JG, Pham T, et al. Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016; 315:788-800.
– reference: 73. Al-Salama ZT, Scott LJ. Baricitinib: A review in rheumatoid arthritis. Drugs. 2018; 78:761-772.
– reference: 4. Rochwerg B, Granton D, Wang DX, et al. High flow nasal cannula compared with conventional oxygen therapy for acute hypoxemic respiratory failure: A systematic review and meta-analysis. Intensive Care Med. 2019; 45:563-572.
– reference: 41. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020; 395:1569- 1578.
– reference: 54. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system. Cytokine Growth Factor Rev. 2020; 53:25-32.
– reference: 17. Leonard S, Atwood CW, Walsh BK, DeBellis RJ, Dungan GC, Strasser W, Whittle JS. Preliminary findings on control of dispersion of aerosols and droplets during high-velocity nasal insufflation therapy using a simple surgical mask: Implications for the high-flow nasal cannula. Chest. 2020; 158:1046-1049.
– reference: 1. World Health Organization. WHO coronavirus (COVID-19) dashboard. https://covid19.who.int (accessed March 15, 2023).
– reference: 53. Salvarani C, Massari M, Costantini M, et al. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia: A double-blind, randomised, placebo-controlled trial. Eur Respir J. 2022; 60:2200025.
– reference: 20. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017; 7:CD004104.
– reference: 18. Katsuno T, Suzuki M, Hojo M, Terada J, Nakamura K, Suzuki T, Miyazato Y, Sugiyama H. Clinical experience with high-flow nasal cannulas for coronavirus disease 2019 patients in Japan. Respir Investig. 2021; 59:569-572.
– reference: 28. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020; 323:2052-2059.
– reference: 51. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Sterne JAC, Murthy S, et al. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A meta-analysis. JAMA. 2020; 324:1330-1341.
– reference: 70. Alam W, Bizri AR. Efficacy of tocilizumab in COVID-19: A review of the current evidence. Sci Prog. 2021; 104:368504211030372.
– reference: 23. Duca A, Memaj I, Zanardi F, Preti C, Alesi A, Della Bella L, Ghezzi E, Di Marco F, Lorini FL, Venturelli S, Fagiuoli S, Cosentini R. Severity of respiratory failure and outcome of patients needing a ventilatory support in the Emergency Department during Italian novel coronavirus SARS-CoV2 outbreak: Preliminary data on the role of Helmet CPAP and Non-Invasive Positive Pressure Ventilation. EClinicalMedicine. 2020; 24:100419.
– reference: 71. WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group; Shankar-Hari M, Vale CL, et al. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA. 2021; 326:499-518.
– ident: 45
  doi: 10.1001/jama.2020.16349
– ident: 70
  doi: 10.1177/00368504211030372
– ident: 9
  doi: 10.1186/s13613-020-00653-z
– ident: 8
  doi: 10.1097/CCM.0000000000004558
– ident: 60
  doi: 10.1001/jamainternmed.2020.6615
– ident: 62
  doi: 10.1056/NEJMoa2030340
– ident: 90
  doi: 10.1001/jama.2021.4152
– ident: 50
  doi: 10.1056/NEJMoa2021436
– ident: 16
  doi: 10.1183/13993003.00892-2020
– ident: 76
  doi: 10.15252/emmm.202012697
– ident: 17
  doi: 10.1016/j.chest.2020.03.043
– ident: 56
  doi: 10.1016/S2665-9913(20)30173-9
– ident: 61
  doi: 10.1056/NEJMoa2028836
– ident: 91
  doi: 10.1136/bmj.n2400
– ident: 57
  doi: 10.1016/j.medmal.2020.05.001
– ident: 15
  doi: 10.1183/13993003.02339-2018
– ident: 49
  doi: 10.1016/S0140-6736(20)30361-5
– ident: 54
  doi: 10.1016/j.cytogfr.2020.05.003
– ident: 82
  doi: 10.1016/j.jacc.2020.04.031
– ident: 11
  doi: 10.1164/rccm.200503-353OC
– ident: 2
  doi: 10.1136/bmj-2021-069317
– ident: 21
  doi: 10.1001/jama.2016.0291
– ident: 29
  doi: 10.1001/jama.2020.5394
– ident: 68
  doi: 10.1007/s11684-020-0824-3
– ident: 32
  doi: 10.1016/S0140-6736(20)31189-2
– ident: 80
  doi: 10.1016/j.jacc.2020.05.001
– ident: 92
  doi: 10.1056/NEJMoa2103417
– ident: 53
  doi: 10.1183/13993003.00025-2022
– ident: 88
  doi: 10.1136/bmj.n311
– ident: 1
– ident: 69
  doi: 10.1111/resp.14106
– ident: 63
  doi: 10.1136/bmj.n84
– ident: 83
  doi: 10.1503/cmaj.201240
– ident: 71
– ident: 81
  doi: 10.1182/blood.2020006000
– ident: 31
  doi: 10.1513/AnnalsATS.202005-427RL
– ident: 30
  doi: 10.1007/s00134-020-06251-8
– ident: 58
  doi: 10.1002/jmv.25801
– ident: 94
  doi: 10.1016/S0140-6736(21)01203-4
– ident: 14
  doi: 10.1164/rccm.201803-0589OC
– ident: 33
  doi: 10.1097/CCM.0000000000004457
– ident: 5
  doi: 10.1007/s12630-020-01740-2
– ident: 40
  doi: 10.1038/s41467-020-20542-0
– ident: 18
  doi: 10.1016/j.resinv.2021.02.011
– ident: 25
  doi: 10.1183/13993003.02524-2020
– ident: 85
  doi: 10.3390/jcm9082489
– ident: 55
  doi: 10.1080/13543784.2020.1840549
– ident: 26
  doi: 10.1183/13993003.01692-2020
– ident: 37
  doi: 10.1186/s13054-021-03540-6
– ident: 74
  doi: 10.1016/j.tips.2020.06.007
– ident: 41
  doi: 10.1016/S0140-6736(20)31022-9
– ident: 38
  doi: 10.1097/CCM.0000000000004600
– ident: 72
– ident: 78
  doi: 10.1016/S2213-2600(21)00331-3
– ident: 10
  doi: 10.1186/s40001-022-00953-z
– ident: 6
  doi: 10.1164/rccm.202005-2007LE
– ident: 42
  doi: 10.1016/S1473-3099(21)00485-0
– ident: 59
  doi: 10.1001/jamainternmed.2021.2209
– ident: 89
  doi: 10.1016/j.jacc.2021.12.023
– ident: 36
  doi: 10.1097/CCE.0000000000000254
– ident: 27
  doi: 10.1016/S2213-2600(16)30093-5
– ident: 39
  doi: 10.1021/acscentsci.0c00489
– ident: 35
  doi: 10.1183/13993003.01426-2022
– ident: 66
  doi: 10.1016/S0140-6736(21)00676-0
– ident: 77
  doi: 10.1056/NEJMoa2031994
– ident: 4
  doi: 10.1007/s00134-019-05590-5
– ident: 67
  doi: 10.1016/S2213-2600(21)00081-3
– ident: 73
  doi: 10.1007/s40265-018-0908-4
– ident: 87
  doi: 10.1016/j.jacc.2020.08.041
– ident: 3
– ident: 34
  doi: 10.1371/journal.pone.0252760
– ident: 79
  doi: 10.1016/S0140-6736(22)01109-6
– ident: 44
  doi: 10.1056/NEJMc2022236
– ident: 23
  doi: 10.1016/j.eclinm.2020.100419
– ident: 86
  doi: 10.1056/NEJMoa2002032
– ident: 65
  doi: 10.1056/NEJMoa2100433
– ident: 84
  doi: 10.1016/j.eclinm.2020.100639
– ident: 19
  doi: 10.1097/CCM.0000000000002361
– ident: 48
  doi: 10.1016/S0140-6736(20)30317-2
– ident: 47
  doi: 10.1038/s41598-020-78054-2
– ident: 13
  doi: 10.1007/s00134-015-3693-5
– ident: 24
  doi: 10.1183/13993003.01935-2020
– ident: 28
  doi: 10.1001/jama.2020.6775
– ident: 7
  doi: 10.1016/j.eclinm.2020.100570
– ident: 51
  doi: 10.1001/jama.2020.17023
– ident: 52
  doi: 10.1016/j.jiac.2022.02.006
– ident: 12
  doi: 10.1007/s00134-013-3194-3
– ident: 20
  doi: 10.1002/14651858.CD004104.pub4
– ident: 75
  doi: 10.1016/S0140-6736(20)30304-4
– ident: 46
– ident: 64
  doi: 10.1056/NEJMoa2028700
– ident: 93
  doi: 10.1001/jamainternmed.2021.6203
– ident: 43
  doi: 10.1056/NEJMoa2023184
– ident: 22
  doi: 10.1183/13993003.02426-2016
SSID ssib042413980
ssj0002512030
ssib044737821
Score 2.2328522
SecondaryResourceType review_article
Snippet The coronavirus disease 2019 (COVID-19) pandemic has affected the world for over 3 years. Treatment options have improved substantially during this period,...
SourceID pubmedcentral
proquest
pubmed
crossref
jstage
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 99
SubjectTerms anticoagulation therapy
high-flow nasal cannula therapy
immune-based agents
remdesivir
Review
Title Treatment options for patients with severe COVID-19
URI https://www.jstage.jst.go.jp/article/ghm/5/2/5_2023.01024/_article/-char/en
https://www.ncbi.nlm.nih.gov/pubmed/37128231
https://www.proquest.com/docview/2808587411
https://pubmed.ncbi.nlm.nih.gov/PMC10130548
Volume 5
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Global Health & Medicine, 2023/04/30, Vol.5(2), pp.99-105
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELZg4YCEEG_CS0HigIRSEj_yECe07GpB291Li3qzHMfZbRditNse4NczfsRNqyItHBpVzqSu5nPG39ieGYTewpyQyaqWSVoJnNC6aMEOpiQp2zSvKVDyymbgG5_kR1P6dcZm6xKcNrpkWY_k751xJf-DKrQBriZK9h-QDT8KDfAd8IUrIAzX62EcTolrdzbFHhr0qVJ93BrMfOpSvd8__fblc-LtxmKY79-HQtoxsL3TPtamAP3cMcyx_qEvdBgHeqFdsM-V-LW6mA-XDzAZ7IRYK4MpoWDxXKXhkdrR5s0kG4wGPDB5rr7RtiUmDGg76O_s3IT7YzIyuevoetLpN9pPTvnh9PiYTw5mk5voFoanyGDNxcynhoGltmhM-F8uR5Pt48NmDxv04vYCGPaZ2uU8bJ-BHZCKyX10z3sD8ScH7QN0Q3UP0V23lBq7CLFHiASYYw9zDDDHPcyxgTl2MMc9zI_R9PBgsn-U-FoXiaQFWcJs2NQqbUVJW0pbYC4MC1KZAsWloKISZS1ICdS-yYloWCVoIVhREyabDKSBfjxBe53u1DMUp0VDMiZz0bKc5oIJUQMPq2RJZQ50j0Zo1KuIS58I3tQj-c7BIbQ65aBTbnTKrU4j9C488NPlQPm76Een8yDoXw4rxzg2nyAdbpoIQ3ihI_SmB4qDlTNbV6JTenXFcQmuQQnsN4vQUwdc6IEUwLHATYlQuQFpEDAZ1DfvdPNzm0k9M_v24LM_v0bHL9Cd9fvzEu0tL1fqFRDSZf3ajtc_JxqI3Q
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Treatment+options+for+patients+with+severe+COVID-19&rft.jtitle=Global+health+%26+medicine&rft.au=Morishita%2C+Momoko&rft.au=Hojo%2C+Masayuki&rft.date=2023-04-30&rft.issn=2434-9194&rft.eissn=2434-9194&rft.volume=5&rft.issue=2&rft.spage=99&rft_id=info:doi/10.35772%2Fghm.2023.01024&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2434-9186&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2434-9186&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2434-9186&client=summon